Biocryst Pharmaceuticals (BCRX) Long-Term Investments (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Long-Term Investments data on file, last reported at $20.6 million in Q1 2026.

• Quarterly Long-Term Investments changed 0.1% year-over-year to $20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.6 million (changed 0.1% YoY) and the FY2025 annual result came in at $61.2 million, up 200.96% from the prior year.
• Long-Term Investments retreated to $20.6 million in Q1 2026, from $61.2 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $64.3 million in Q2 2024 to a low of $3.4 million in Q1 2023.
• A 5-year average of $26.3 million and a median of $20.4 million in 2024 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments jumped 1766.97% — and 2025, when it slumped 84.29%.
• Tracing BCRX's Long-Term Investments over 5 years: stood at $18.1 million in 2022, then plunged by 80.94% to $3.4 million in 2023, then surged by 489.93% to $20.3 million in 2024, then surged by 200.96% to $61.2 million in 2025, then plunged by 66.37% to $20.6 million in 2026.
• The last three Long-Term Investments figures came in at $20.6 million (Q1 2026), $61.2 million (Q4 2025), and $39.7 million (Q3 2025), per Business Quant data.